Main content

    Prostate Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Adjuvant Therapy  |  Metastatic Prostate Cancer


    Active Trials

    Adjuvant Therapy

    Title: A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
    Description: Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
    Investigators: NCI - National Cancer Institute
    Eligibility: Male subjects who have histologic documentation of prostatic cancer
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study CALGB 90203

    Back to top

    Active Trials

    Metastatic Prostate Cancer

    Title: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
    Description: The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
    Investigator: Ari Baron, MD
    Eligibility: Male subjects 18 y/o and older with a clinical diagnosis of metastatic prostate cancer
    Status: Active and open to enrollment
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study S1216

    Title: A Phase Ib, Open-label, Dose-escalation Study of the Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors
    Description: This is an open-label, multicenter, Phase Ib, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of oral GDC-0068 administered in combination with either docetaxel, mFOLFOX6, paclitaxel or enzalutamide in patients with advanced or metastatic solid tumors for which standard therapy either does not exist or has proven ineffective or intolerable.
    Investigator: Ari Baron, MD
    Eligibility: Male subjects 18 y/o and older with a clinical diagnosis of metastatic castration resistant prostate cancer
    Status: Active and open to enrollment
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study Genentech PAM4983g

    Title: A Phase Ib/II Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
    Description: Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
    Investigator: Ari Baron, MD
    Eligibility: Male subjects 18 y/o and older with histologically or cytologically confirmed metastatic or advanced prostate adenocarcinoma that has been previously treated with docetaxel and has progressed during treatment of at least one hormonal therapy
    Status: Active and open to enrollment
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study Genentech GO27983

    Title: A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
    Description: A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
    Investigator: Ari Baron, MD
    Eligibility: Male subjects 18 y/o and older with histologic documentation of adenocarcinoma of the prostate
    Status: Active and open to enrollment
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study Genentech DST4964G

    Title: A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
    Description: This randomized phase III trial is studying prostate radiation therapy to see how well it works compared with short-term androgen deprivation therapy given together with pelvic lymph node radiation therapy with or without prostate radiation therapy in treating patients with a rising PSA after surgery for prostate cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Male subjects 18 y/o and older with a diagnosis of adenocarcinoma of the prostate treated primarily with radical prostatectomy
    Status: Call site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study RTOG 0534

    Title: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer
    Description: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Male subjects 18 y/o and older with a histologically confirmed adenocarcinoma of the prostate diagnosed within the past 180 days and at intermediate-risk for recurrence
    Status: Call site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study RTOG 0815

    Title: A Phase 2, Randomized, Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who Are Asymptomatic or Minimally Symptomatic
    Description: The purpose of this study is to examine the safety and effectiveness (how well the drug works) of two different doses (3 mg/kg and 10 mg/kg) of Ipilimumab (Yervoy™) in patients with metastatic castration resistant prostate cancer
    Investigator: Ari Baron, MD
    Eligibility: Male subjects, 18 y/o and older, with prostate cancer with metastases, prostate cancer should be castration resistant and have progression during hormonal therapy
    Status: Active and open to enrollment
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study BMS CA184-437

    • updated December 2014

    Back to top